• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Genmab A/S - American Depositary Shares (NQ:GMAB)

    28.64 +0.12 (+0.42%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,666,074
    Open 28.12
    Bid (Size) 27.30 (100)
    Ask (Size) 28.78 (300)
    Prev. Close 28.52
    Today's Range 28.03 - 28.67
    52wk Range 21.00 - 35.43
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    From Genmab A/S and AbbVie
    Via Business Wire
    News headline image
    Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
    From Genmab A/S
    Via Business Wire

    Performance

    YTD
    -10.0%
    -10.0%
    1 Month
    +10.1%
    +10.1%
    3 Month
    +9.7%
    +9.7%
    6 Month
    -13.0%
    -13.0%
    1 Year
    +26.7%
    +26.7%

    More News

    Read More
    Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case ↗
    Via Chartmill
    GENMAB A/S -SP ADR (NASDAQ:GMAB) Emerges as a Peter Lynch-Style GARP Investment ↗
    Via Chartmill
    Genmab A/S (NASDAQ:GMAB): A GARP Case Study in Affordable Biotech Growth ↗
    Via Chartmill
    GENMAB A/S (NASDAQ:GMAB) Stands Out as a Peter Lynch-Style GARP Investment ↗
    Via Chartmill
    GENMAB A/S -SP ADR (NASDAQ:GMAB) Combines Strong Growth with Bullish Technical Formation ↗
    Via Chartmill
    News headline image
    Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
    From Genmab A/S
    Via Business Wire
    News headline image
    Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
    From Genmab A/S
    Via Business Wire
    News headline image
    Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
    From Genmab
    Via Business Wire
    News headline image
    Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
    From Genmab A/S
    Via Business Wire
    News headline image
    Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
    From Genmab A/S
    Via Business Wire
    News headline image
    Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗
    Via The Motley Fool
    GENMAB A/S (NASDAQ:GMAB) Presents a Compelling Blend of Strong Fundamentals and Bullish Technicals ↗
    Via Chartmill
    GENMAB A/S -SP ADR (NASDAQ:GMAB) Passes Peter Lynch's GARP Investment Screen ↗
    Via Chartmill
    News headline image
    AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown
    Via MarketMinute
    Topics ETFs Economy Intellectual Property
    News headline image
    My Top 4 Stocks to Buy in Early 2026 ↗
    Via The Motley Fool
    Topics Artificial Intelligence Economy
    News headline image
    Genmab Reports Mixed Results From Late-Stage Trial Of Lymphoma Drug ↗
    Via Stocktwits
    News headline image
    Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    From Genmab A/S
    Via Business Wire
    News headline image
    Why Are Investors Paying Attention To Genmab Stock? ↗
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
    From Genmab A/S
    Via Business Wire
    News headline image
    Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech ↗
    Via Stocktwits
    Topics Supply Chain
    News headline image
    Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
    Via MarketMinute
    Topics ETFs Intellectual Property
    News headline image
    Genmab Portfolio Prioritization Update
    From Genmab A/S
    Via Business Wire
    News headline image
    Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
    From Genmab A/S
    Via Business Wire

    Frequently Asked Questions

    Is Genmab A/S - American Depositary Shares publicly traded?
    Yes, Genmab A/S - American Depositary Shares is publicly traded.
    What exchange does Genmab A/S - American Depositary Shares trade on?
    Genmab A/S - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Genmab A/S - American Depositary Shares?
    The ticker symbol for Genmab A/S - American Depositary Shares is GMAB on the Nasdaq Stock Market
    What is the current price of Genmab A/S - American Depositary Shares?
    The current price of Genmab A/S - American Depositary Shares is 28.64
    When was Genmab A/S - American Depositary Shares last traded?
    The last trade of Genmab A/S - American Depositary Shares was at 07/30/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.